# CUREVERSE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cureverse

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.cureverse.co.kr/
- Total disclosed funding: $17M
- Latest round: Series B (Jan 18, 2025)
- Investors on record: 7

## About

Based in Seoul, South Korea, CUREVERSE Inc. was founded in 2021 and is headquartered at the Korea Institute of Science and Technology (KIST). The company specializes in discovering and developing novel small-molecule drug candidates targeting difficult-to-treat diseases. Guided by its proprietary “Right Structure” philosophy, Cureverse aims to address the root causes of diseases rather than merely treating symptoms. Its pipeline includes therapies for Alzheimer's disease, multiple sclerosis, cancer, fibrosis, and metabolic and inflammatory disorders. The company has attracted venture capital backing and completed a Series B financing round in January 2025, followed by an accelerator/incubator investment round in July 2025.
The company focuses on the discovery and development of small-molecule therapeutics for neurodegenerative, autoimmune, oncological, and metabolic diseases. Its pipeline includes CV-01, a first-in-class Nrf2 activator; CV-02, a best-in-class S1P1-targeting treatment; CV-03, an immuno-oncology candidate; and additional programs targeting fibrosis, metabolic disorders, and tau-related neurodegenerative diseases. In addition to internal drug development, Cureverse pursues licensing, co-development, and technology transfer opportunities with domestic and international pharmaceutical companies.
The company's revenue is generated primarily through the development and commercialization of proprietary drug candidates, as well as potential licensing-out agreements, joint development partnerships, technology transfers, and strategic collaborations with pharmaceutical companies. The company actively pursues business development opportunities around its drug discovery platform and pipeline assets.
The company plans to advance its clinical pipeline, particularly its neurodegenerative and autoimmune disease programs, while expanding licensing and co-development opportunities with global pharmaceutical partners. The company will use the funding to accelerate the development of its small-molecule drug candidates, support clinical studies, expand research capabilities, and pursue strategic partnerships and technology-transfer opportunities for its key pipeline assets.

## Funding rounds

- Series B, Jan 18, 2025, $17M — Yuanta Investment, Partners Investment, Daekyo Investment, Solidus Investment, UTC Investment, STIC Ventures, Gradiant

## Investors

- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series B
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series B
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series B
- Solidus Investment (https://capitalatlas.ai/funds/solidus-investment) — Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series B
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series B
- Gradiant — Series B